

### ***Amendments to the Claims***

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1 to 77 (Canceled).

78. (New) A method of inducing apoptosis of a DR5-expressing cell, comprising contacting said cell with an agonist antibody or fragment thereof that specifically binds to a polypeptide consisting of amino acids 1 to 133 of SEQ ID NO:2.

79. (New) The method of claim 78 which is *in vitro*.

80. (New) The method of claim 78 which is *in vivo*.

81. (New) The method of claim 78, wherein the polypeptide is glycosylated.

82. (New) The method of claim 78, wherein said antibody or fragment thereof is polyclonal.

83. (New) The method of claim 78, wherein said antibody or fragment thereof is monoclonal.

84. (New) The method of claim 78, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

85. (New) The method of claim 78, wherein said antibody or fragment thereof is labeled.

86. (New) The method of claim 85, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

87. (New) The method of claim 78, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

88. (New) The method of claim 78, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

89. (New) The method of claim 78, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

90. (New) The method of claim 89, wherein said compound is TRAIL.

91. (New) The method of claim 89, wherein said compound is a chemotherapeutic drug.

92. (New) A method of inducing apoptosis of a DR5-expressing cell, comprising contacting said cell with an agonist antibody or fragment thereof that specifically binds to a DR5 polypeptide expressed on the surface of a cell, wherein said polypeptide is encoded by a polynucleotide encoding amino acids -51 to 360 of SEQ ID NO:2.

93. (New) The method of claim 92 which is *in vitro*,

94. (New) The method of claim 92 which is *in vivo*.

95. (New) The method of claim 92, wherein the polypeptide is glycosylated.
96. (New) The method of claim 92, wherein said antibody or fragment thereof is polyclonal.
97. (New) The method of claim 92, wherein said antibody or fragment thereof is monoclonal.
98. (New) The method of claim 92, wherein said antibody or fragment thereof is selected from the group consisting of:
- (a) a chimeric antibody;
  - (b) a Fab fragment; and
  - (c) a F(ab')<sub>2</sub> fragment.
99. (New) The method of claim 92, wherein said antibody or fragment thereof is labeled.
100. (New) The method of claim 99, wherein said label is selected from the group consisting of:
- (a) an enzyme;
  - (b) a fluorescent label; and
  - (c) a radioisotope.
101. (New) The method of claim 92, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.
102. (New) The method of claim 92, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.
103. (New) The method of claim 92, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

104. (New) The method of claim 103, wherein said compound is TRAIL.

105. (New) The method of claim 103, wherein said compound is a chemotherapeutic drug.

106. (New) A method of inducing apoptosis of a DR5-expressing cell, comprising contacting said cell with an agonist antibody or fragment thereof that specifically binds the extracellular domain of the polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97920.

107. (New) The method of claim 106 which is *in vitro*.

108. (New) The method of claim 106 which is *in vivo*.

109. (New) The method of claim 106, wherein the polypeptide is glycosylated.

110. (New) The method of claim 106, wherein said antibody or fragment thereof is polyclonal.

111. (New) The method of claim 106, wherein said antibody or fragment thereof is monoclonal.

112. (New) The method of claim 106, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

113. (New) The method of claim 106, wherein said antibody or fragment thereof is labeled.

114. (New) The method of claim 113, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

115. (New) The method of claim 106, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

116. (New) The method of claim 106, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

117. (New) The method of claim 106, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

118. (New) The method of claim 117, wherein said compound is TRAIL.

119. (New) The method of claim 117, wherein said compound is a chemotherapeutic drug.

120. (New) A method of inducing apoptosis of a DR5-expressing cell comprising contacting said cell with an agonist antibody or fragment thereof that specifically binds to a DR5 polypeptide expressed on the surface of a cell, wherein said polypeptide is encoded by a polynucleotide encoding the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97920.

121. (New) The method of claim 120 which is *in vitro*.

122. (New) The method of claim 120 which is *in vivo*.

123. (New) The method of claim 120, wherein the polypeptide is glycosylated.
124. (New) The method of claim 120, wherein said antibody or fragment thereof is polyclonal.
125. (New) The method of claim 120, wherein said antibody or fragment thereof is monoclonal.
126. (New) The method of claim 120, wherein said antibody or fragment thereof is selected from the group consisting of:
- (a) a chimeric antibody;
  - (b) a Fab fragment; and
  - (c) a F(ab')<sub>2</sub> fragment.
127. (New) The method of claim 120, wherein said antibody or fragment thereof is labeled.
128. (New) The method of claim 127, wherein said label is selected from the group consisting of:
- (a) an enzyme;
  - (b) a fluorescent label; and
  - (c) a radioisotope.
129. (New) The method of claim 120, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.
130. (New) The method of claim 120, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.
131. (New) The method of claim 120, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

132. (New) The method of claim 131, wherein said compound is TRAIL.

133. (New) The method of claim 131, wherein said compound is a chemotherapeutic drug.

134. (New) A method of treating cancer, comprising administering to a patient an agonist antibody or fragment thereof that specifically binds to a polypeptide consisting of amino acids 1 to 133 of SEQ ID NO:2, wherein said antibody or fragment thereof is administered in an amount sufficient to induce apoptosis of a DR5-expressing cancer cell.

135. (New) The method of claim 134, wherein the polypeptide is glycosylated.

136. (New) The method of claim 134, wherein said antibody or fragment thereof is polyclonal.

137. (New) The method of claim 134, wherein said antibody or fragment thereof is monoclonal.

138. (New) The method of claim 134, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

139. (New) The method of claim 134, wherein said antibody or fragment thereof is labeled.

140. (New) The method of claim 139, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

141. (New) The method of claim 134, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

142. (New) The method of claim 134, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

143. (New) The method of claim 134, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

144. (New) The method of claim 143, wherein said compound is TRAIL.

145. (New) The method of claim 143, wherein said compound is a chemotherapeutic drug.

146. (New) A method of treating cancer, comprising administering to a patient an agonist antibody or fragment thereof that specifically binds to a DR5 polypeptide expressed on the surface of a cell, wherein said polypeptide is encoded by a polynucleotide encoding amino acids -51 to 360 of SEQ ID NO:2, and wherein said antibody or fragment thereof is administered in an amount sufficient to induce apoptosis of a DR5-expressing cancer cell.

147. (New) The method of claim 146, wherein the polypeptide is glycosylated.



148. (New) The method of claim 146, wherein said antibody or fragment thereof is polyclonal.

149. (New) The method of claim 146, wherein said antibody or fragment thereof is monoclonal.

150. (New) The method of claim 146, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

151. (New) The method of claim 146, wherein said antibody or fragment thereof is labeled.

152. (New) The method of claim 151, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

153. (New) The method of claim 146, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

154. (New) The method of claim 146, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

155. (New) The method of claim 146, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

156. (New) The method of claim 155, wherein said compound is TRAIL.

157. (New) The method of claim 155, wherein said compound is a chemotherapeutic drug.

158. (New) A method of treating cancer, comprising administering to a patient an agonist antibody or fragment thereof that specifically binds the extracellular domain of the polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97920, wherein said antibody or fragment thereof is administered in an amount sufficient to induce apoptosis of a DR5-expressing cancer cell.

159. (New) The method of claim 158, wherein the polypeptide is glycosylated.

160. (New) The method of claim 158, wherein said antibody or fragment thereof is polyclonal.

161. (New) The method of claim 158, wherein said antibody or fragment thereof is monoclonal.

162. (New) The method of claim 158, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

163. (New) The method of claim 158, wherein said antibody or fragment thereof is labeled.

164. (New) The method of claim 163, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

165. (New) The method of claim 158, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

166. (New) The method of claim 158, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

167. (New) The method of claim 158, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

168. (New) The method of claim 167, wherein said compound is TRAIL.

169. (New) The method of claim 167, wherein said compound is a chemotherapeutic drug.

170. (New) A method of treating cancer, comprising administering to a patient an agonist antibody or fragment thereof that specifically binds to DR5 polypeptide expressed on the surface of a cell, wherein said polypeptide is encoded by a polynucleotide encoding the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97920, and wherein said antibody or fragment thereof is administered in an amount sufficient to induce apoptosis of a DR5-expressing cancer cell.

171. (New) The method of claim 170, wherein the polypeptide is glycosylated.

172. (New) The method of claim 170, wherein said antibody or fragment thereof is polyclonal.

173. (New) The method of claim 170, wherein said antibody or fragment thereof is monoclonal.

174. (New) The method of claim 170, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

175. (New) The method of claim 170, wherein said antibody or fragment thereof is labeled.

176. (New) The method of claim 175, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

177. (New) The method of claim 170, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

178. (New) The method of claim 170, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

179. (New) The method of claim 170, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

180. (New) The method of claim 179, wherein said compound is TRAIL.

181. (New) The method of claim 179, wherein said compound is a chemotherapeutic drug.

182. (New) A method of inducing apoptosis of a DR5-expressing cell, comprising contacting said cell with an antibody or fragment thereof that specifically binds to a polypeptide consisting of amino acids 1 to 133 of SEQ ID NO:2.

183. (New) The method of claim 182 which is *in vitro*.

184. (New) The method of claim 182 which is *in vivo*.

185. (New) The method of claim 182, wherein the polypeptide is glycosylated.

186. (New) The method of claim 182, wherein said antibody or fragment thereof is polyclonal.

187. (New) The method of claim 182, wherein said antibody or fragment thereof is monoclonal.

188. (New) The method of claim 182, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

189. (New) The method of claim 182, wherein said antibody or fragment thereof is labeled.

190. (New) The method of claim 189, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

191. (New) The method of claim 182, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

192. (New) The method of claim 182, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

193. (New) The method of claim 182, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

194. (New) The method of claim 193, wherein said compound is TRAIL.

195. (New) The method of claim 193, wherein said compound is a chemotherapeutic drug.

196. (New) A method of inducing apoptosis of a DR5-expressing cell, comprising contacting said cell with an antibody or fragment thereof that specifically binds to a DR5 polypeptide expressed on the surface of a cell, wherein said polypeptide is encoded by a polynucleotide encoding amino acids -51 to 360 of SEQ ID NO:2.

197. (New) The method of claim 196 which is *in vitro*.

198. (New) The method of claim 196 which is *in vivo*.

199. (New) The method of claim 196, wherein the polypeptide is glycosylated.

200. (New) The method of claim 196, wherein said antibody or fragment thereof is polyclonal.

201. (New) The method of claim 196, wherein said antibody or fragment thereof is monoclonal.

202. (New) The method of claim 196, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

203. (New) The method of claim 196, wherein said antibody or fragment thereof is labeled.

204. (New) The method of claim 203, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

205. (New) The method of claim 196, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

206. (New) The method of claim 196, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

207. (New) The method of claim 196, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

208. (New) The method of claim 207, wherein said compound is TRAIL.

209. (New) The method of claim 207, wherein said compound is a chemotherapeutic drug.

210. (New) A method of inducing apoptosis of a DR5-expressing cell, comprising contacting said cell with an antibody or fragment thereof that specifically binds the extracellular domain of the polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97920.

211. (New) The method of claim 210 which is *in vitro*.

212. (New) The method of claim 210 which is *in vivo*.

213. (New) The method of claim 210, wherein the polypeptide is glycosylated.

214. (New) The method of claim 210, wherein said antibody or fragment thereof is polyclonal.

215. (New) The method of claim 210, wherein said antibody or fragment thereof is monoclonal.

216. (New) The method of claim 210, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

217. (New) The method of claim 210, wherein said antibody or fragment thereof is labeled.



218. (New) The method of claim 217, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

219. (New) The method of claim 210, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

220. (New) The method of claim 210, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

221. (New) The method of claim 210, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

222. (New) The method of claim 221, wherein said compound is TRAIL.

223. (New) The method of claim 221, wherein said compound is a chemotherapeutic drug.

224. (New) A method of inducing apoptosis of a DR5-expressing cell comprising contacting said cell with an antibody or fragment thereof that specifically binds to DR5 polypeptide expressed on the surface of a cell, wherein said polypeptide is encoded by a polynucleotide encoding the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97920.

225. (New) The method of claim 224 which is *in vitro*.

226. (New) The method of claim 224 which is *in vivo*.

227. (New) The method of claim 224, wherein the polypeptide is glycosylated.

228. (New) The method of claim 224, wherein said antibody or fragment thereof is polyclonal.

229. (New) The method of claim 224, wherein said antibody or fragment thereof is monoclonal.

230. (New) The method of claim 224, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

231. (New) The method of claim 224, wherein said antibody or fragment thereof is labeled.

232. (New) The method of claim 231, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

233. (New) The method of claim 224, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

234. (New) The method of claim 224, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

235. (New) The method of claim 224, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

236. (New) The method of claim 235, wherein said compound is TRAIL.

237. (New) The method of claim 235, wherein said compound is a chemotherapeutic drug.

238. (New) A method of treating cancer, comprising administering to a patient an antibody or fragment thereof that specifically binds to a polypeptide consisting of amino acids 1 to 133 of SEQ ID NO:2, wherein said antibody or fragment thereof is administered in an amount sufficient to induce apoptosis of a DR5-expressing cancer cell.

239. (New) The method of claim 238, wherein the polypeptide is glycosylated.

240. (New) The method of claim 238, wherein said antibody or fragment thereof is polyclonal.

241. (New) The method of claim 238, wherein said antibody or fragment thereof is monoclonal.

242. (New) The method of claim 238, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

243. (New) The method of claim 238, wherein said antibody or fragment thereof is labeled.

244. (New) The method of claim 243, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

245. (New) The method of claim 238, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

246. (New) The method of claim 238, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

247. (New) The method of claim 238, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

248. (New) The method of claim 247, wherein said compound is TRAIL.

249. (New) The method of claim 247, wherein said compound is a chemotherapeutic drug.

250. (New) A method of treating cancer, comprising administering to a patient an antibody or fragment thereof that specifically binds to a DR5 polypeptide expressed on the surface of a cell, wherein said polypeptide is encoded by a polynucleotide encoding amino acids -51 to 360 of SEQ ID NO:2, wherein said antibody or fragment thereof is administered in an amount sufficient to induce apoptosis of a DR5-expressing cancer cell.

251. (New) The method of claim 250, wherein the polypeptide is glycosylated.

252. (New) The method of claim 250, wherein said antibody or fragment thereof is polyclonal.

253. (New) The method of claim 250, wherein said antibody or fragment thereof is monoclonal.

254. (New) The method of claim 250, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

255. (New) The method of claim 250, wherein said antibody or fragment thereof is labeled.

256. (New) The method of claim 255, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

257. (New) The method of claim 250, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

258. (New) The method of claim 250, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

259. (New) The method of claim 250, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

260. (New) The method of claim 259, wherein said compound is TRAIL.

261. (New) The method of claim 259, wherein said compound is a chemotherapeutic drug.

262. (New) A method of treating cancer, comprising administering to a patient an antibody or fragment thereof that specifically binds the extracellular domain of the polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97920, wherein said antibody or fragment thereof is administered in an amount sufficient to induce apoptosis of a DR5-expressing cancer cell.

263. (New) The method of claim 262, wherein the polypeptide is glycosylated.

264. (New) The method of claim 262, wherein said antibody or fragment thereof is polyclonal.

265. (New) The method of claim 262, wherein said antibody or fragment thereof is monoclonal.

266. (New) The method of claim 262, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

267. (New) The method of claim 262, wherein said antibody or fragment thereof is labeled.

268. (New) The method of claim 267, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

269. (New) The method of claim 262, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

270. (New) The method of claim 262, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

271. (New) The method of claim 262, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:

- (a) TRAIL; and
- (b) a chemotherapeutic drug.

272. (New) The method of claim 271, wherein said compound is TRAIL.

273. (New) The method of claim 271, wherein said compound is a chemotherapeutic drug.

274. (New) A method of treating cancer, comprising administering to a patient an antibody or fragment thereof that specifically binds to DR5 polypeptide expressed on the surface of a cell, wherein said polypeptide is encoded by a polynucleotide encoding the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97920, wherein said antibody or fragment thereof is administered in an amount sufficient to induce apoptosis of a DR5-expressing cancer cell.

275. (New) The method of claim 274, wherein the polypeptide is glycosylated.

276. (New) The method of claim 274, wherein said antibody or fragment thereof is polyclonal.

277. (New) The method of claim 274, wherein said antibody or fragment thereof is monoclonal.

278. (New) The method of claim 274, wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a Fab fragment; and
- (c) a F(ab')<sub>2</sub> fragment.

279. (New) The method of claim 274, wherein said antibody or fragment thereof is labeled.

280. (New) The method of claim 279, wherein said label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label; and
- (c) a radioisotope.

281. (New) The method of claim 274, wherein said antibody or fragment thereof specifically binds to said polypeptide in a Western blot.

282. (New) The method of claim 274, wherein said antibody or fragment thereof specifically binds to said polypeptide in an ELISA.

283. (New) The method of claim 274, further comprising contacting said cell with a compound that potentiates apoptosis selected from the group consisting of:



- (a) TRAIL; and
- (b) a chemotherapeutic drug.

284. (New) The method of claim 283, wherein said compound is TRAIL.

285. (New) The method of claim 283, wherein said compound is a chemotherapeutic drug.